LAUSR

INTRODUCTION : There is very limited knowledge about the safety of COVID-19 vaccines in patients with psoriasis who are being treated with biological agents. We present our experience in 369 patients with moderate-to-severe psoriasis undergoing therapy with anti-IL agents who were vaccinated against SARS-CoV-2. AREAS COVERED : None of the 369 patients referred any serious adverse event related to vaccination against COVID-19, while about one-third reported mild adverse events similar to those seen in the general population that resolved within 48 hours. No patient discontinued biological therapy to receive a COVID-19 vaccine. EXPERT OPINION : Our observations provide evidence that COVID-19 vaccines can be considered safe in patients with moderate-to-severe psoriasis who are receiving anti-IL therapy.